Risk/benefit ratio of new immunotherapy strategies

The increase in knowledge about the way the immune system functions is leading to exciting new therapeutic possibilities for cancer patients. A panel of experts met during the ESMO Symposium on Immuno-Oncology to discuss about risk/benefit of: Vaccines, Checkpoint inhibitors, and Adoptive T cell transfer. Read the panel discussion and/or view the webcast here.